about
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.A randomized trial of mesenchymal stem cells in multiple system atrophy.The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen.The role of radiotherapy in the management of POEMS syndrome.Serum microRNA-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromesLymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapyPrediction of survival by applying current prognostic models in diffuse large B-cell lymphoma treated with R-CHOP followed by autologous transplantation.An unusual case of spontaneous remission of Hodgkin's disease after a single cycle of COPP-ABV chemotherapy followed by infectious complicationsPrognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic SyndromeSingle monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotypeRadiotherapy as an effective treatment modality for follicular lymphoma: a single institution experience.Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance.Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based RegimensLong-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.Therapeutic comparison of chemotherapy and surgery for early stage diffuse large B-cell gastric lymphoma.Nine-year survival of lymphoblastic lymphoma patientsClinical outcomes and prognostic factors of empirical antifungal therapy with itraconazole in the patients with hematological malignancies: a prospective multicenter observational study in Korea.Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.Diagnostic Accuracy of Cerebrospinal Fluid (CSF) Cytology in Metastatic Tumors: An Analysis of Consecutive CSF SamplesSuccess rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in KoreaPatterns of care and treatment outcomes for primary thyroid lymphoma: a single institution study.Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of "RISK" Study.Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience.Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome.Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients.Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes.The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma.Clinical significance of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells.The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.Aurora-A kinase inhibition enhances the cytosine arabinoside-induced cell death in leukemia cells through apoptosis and mitotic catastrophe.Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study.Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia.High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from theTear Cytokines as Biomarkers for Chronic Graft-versus-Host Disease.Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine.The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma.A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma.
P50
Q33394772-878D321A-92D6-43DE-AFC1-BE7FC2D7A64EQ33411923-E6EC784F-CC14-4042-B343-4E0E807BC272Q33434435-6CDED7D4-0A1C-4403-AFD6-AB22BABCB15CQ34290126-B1585B62-E813-43CF-94A7-C4AD85B5B90CQ34384335-A9821331-A584-4072-B549-5F1366E8EF74Q34620383-BFD4BA36-E79A-4C9E-BAED-0EF3957A4315Q35087659-8904E10B-97E5-4A37-8939-83A82DEE5C35Q35207251-F9046A1A-1908-4DB0-B722-E6AFCBCBE2E6Q36128165-A951DE98-8CF4-4419-A495-8162E6FB3B11Q36179427-8FEFB889-9265-47F8-A95A-312083696EAEQ36185741-C772254E-9202-4E35-A694-F85D08AD1C9EQ36254242-7393F266-A48D-4670-9AE4-9F70CD6DDD3AQ36448074-F191028C-E286-4129-98E2-DCA5C796052EQ36722227-E1560AE9-9984-495B-B276-DD9E856E820CQ36735810-2AD98409-F4D2-4A4A-A1BB-CA7B4188ECCCQ37065113-0C343A95-2E9B-41D2-BBD6-D6258891B944Q37065745-83E45047-F828-4C37-889C-7B9DCA3B8E67Q37205603-ED9B3FAB-409F-46D6-8592-0997E3E3D8CAQ37418841-14A13410-E0AD-435E-BA7A-90E7054B599EQ37438385-0DE58E40-5413-4064-8237-1CF8183B50F8Q37459138-265234FA-E74E-4776-9E43-ED30C03AFA08Q37473671-3DA39785-6322-4907-830A-E32D13085B4CQ37549480-C54BCA73-4505-45E6-BD76-241377549940Q38401468-7B66ACB4-D7F1-4FD3-B3CC-27C62FD07054Q38406744-6B3B8BE0-876C-40CB-871F-8B266272BB6AQ38425292-3B176569-5DCA-4C15-98A6-CC9B83706F18Q38436591-49FD087C-C693-44BF-9676-F39E9E502D6BQ38455680-7CC502B8-F368-4702-9D65-663F8FAD49DCQ38784265-66FB8060-5074-4E62-BFCA-3D0383528CD5Q38941414-DA72F5F3-02F1-42B3-A15A-B51315713E9CQ39668893-347DB08F-56DE-47C7-B359-A82F51A9F16AQ39669214-694210C9-4CED-4F74-BE7D-C265AEDAC332Q39693181-E3184D8C-460A-4ECB-83B6-86F0D73BEE42Q39732854-CEF93749-5AD1-478E-B826-3AFBC07EBB44Q40172956-7D5DA129-F23E-44E9-930C-0E414999C77DQ40230959-17088AE8-936B-4779-ADFC-082E4C5EB5C2Q40612184-E0D392CB-B5C2-4498-9B37-566E4C3AAD95Q40695745-E84FE058-93F0-43F0-9DC2-3E252C5DB7B7Q40831533-75E93224-4467-438A-BB20-DBEE0D5E281EQ40885663-CBFD8204-9FD5-4C05-9B82-6F677A876077
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
June-Won Cheong
@ast
June-Won Cheong
@en
June-Won Cheong
@es
June-Won Cheong
@nl
type
label
June-Won Cheong
@ast
June-Won Cheong
@en
June-Won Cheong
@es
June-Won Cheong
@nl
prefLabel
June-Won Cheong
@ast
June-Won Cheong
@en
June-Won Cheong
@es
June-Won Cheong
@nl
P31
P496
0000-0002-1744-0921